ADC Therapeutics Company Insiders
ADCT Stock | USD 1.56 0.04 2.50% |
ADC Therapeutics employs about 273 people. The company is managed by 36 executives with a total tenure of roughly 165 years, averaging almost 4.0 years of service per executive, having 7.58 employees per reported executive. Breaking down ADC Therapeutics' management performance can provide insight into the firm performance.
ADC |
ADC Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2117) % which means that it has lost $0.2117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0553) %, meaning that it created substantial loss on money invested by shareholders. ADC Therapeutics' management efficiency ratios could be used to measure how well ADC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.ADC Therapeutics Workforce Comparison
ADC Therapeutics SA is number one stock in number of employees category among its peers. The total workforce of Information Technology industry is presently estimated at about 4,343. ADC Therapeutics holds roughly 273 in number of employees claiming about 6% of equities under Information Technology industry.
The company has Profit Margin (PM) of (3.0) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.93) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.93. ADC Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ADC Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADC Therapeutics Notable Stakeholders
An ADC Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ADC Therapeutics often face trade-offs trying to please all of them. ADC Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ADC Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Martin | Chief Executive Officer, Executive Director | Profile | |
Chris Martin | Chief Executive Officer, Member of the Board of Directors | Profile | |
Ron Squarer | Non-Executive Chairman of the Board | Profile | |
Michael Forer | Vice Chairman of the Board of Directors, Executive Vice President, Chief Financial Officer | Profile | |
Jennifer Herron | Senior Vice President, Chief Commercial Officer | Profile | |
Patrick Berkel | Senior Vice President, Research & Development | Profile | |
Jennifer Creel | Chief Financial Officer | Profile | |
Viviane Monges | Non-Executive Independent Director | Profile | |
Thomas Pfisterer | Non-Executive Independent Director | Profile | |
Tyrell Rivers | Non-Executive Independent Director | Profile | |
Peter Hug | Non-Executive Independent Director | Profile | |
Victor Sandor | Non-Executive Independent Director | Profile | |
Peter Corr | Non-Executive Independent Director | Profile | |
Kimberly Pope | Chief Human Resource Officer, Senior Vice President | Profile | |
Thomas Rinderknecht | Non-Executive Independent Director | Profile | |
Peter Greaney | Head of Corporate Development | Profile | |
Lisa Skelton | Vice President - Global Project Management | Profile | |
Joseph Camardo | Senior Vice President Chief Medical Officer | Profile | |
Michael Mulkerrin | Chief Officer | Profile | |
David Ege | Chief Officer | Profile | |
Mohamed MD | Chief Officer | Profile | |
Robert Schmidt | Vice President Corporate Controller & Chief Accounting Officer | Profile | |
MS MBA | CEO Director | Profile | |
Peter Esq | Secretary Officer | Profile | |
Stephane Henchoz | Director of Finance | Profile | |
Stephen Evansfreke | Non-Executive Independent Director | Profile | |
Marcy Graham | Investor Officer | Profile | |
Amanda Hamilton | Investor Officer | Profile | |
Jose MBA | Chief Officer | Profile | |
Susan Romanus | Chief Compliance Officer | Profile | |
Jacques Theurillat | Non-Executive Independent Director | Profile | |
Kristen HarringtonSmith | Chief Officer | Profile | |
Richard Onyett | Vice President - Business Development | Profile | |
Dr DPHIL | CoFounder Director | Profile | |
Eugenia Litz | Vice Communications | Profile | |
Lisa Kallebo | Corporate Officer | Profile |
About ADC Therapeutics Management Performance
The success or failure of an entity such as ADC Therapeutics often depends on how effective the management is. ADC Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ADC management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ADC management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 312 people.
Please note, the imprecision that can be found in ADC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADC Therapeutics SA. Check ADC Therapeutics' Beneish M Score to see the likelihood of ADC Therapeutics' management manipulating its earnings.
ADC Therapeutics Workforce Analysis
Traditionally, organizations such as ADC Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ADC Therapeutics within its industry.ADC Therapeutics Manpower Efficiency
Return on ADC Therapeutics Manpower
Revenue Per Employee | 254.8K | |
Revenue Per Executive | 1.9M | |
Net Loss Per Employee | 879.3K | |
Net Loss Per Executive | 6.7M | |
Working Capital Per Employee | 984K | |
Working Capital Per Executive | 7.5M |
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.